ARCH Venture Partners IX Overage, L.P. insider trades
ARCH Venture Partners IX Overage, L.P. has filed 2 Form 4s with the SEC that we hold, for Lyell Immunopharma, Inc. (LYEL) (10% owner) and Vir Biotechnology, Inc. (VIR) (10% owner). Across all of them we count 1 purchase worth $12.5M and 0 sales worth $0 reported on Form 4. In the last 12 months: 1 purchase ($12.5M) and 0 sales ($0). The largest single trade was a purchase of 488,090 shares of Lyell Immunopharma, Inc. worth $12.5M, dated 2026-03-06. The first filing on our record is dated 2022-06-10 and the latest 2026-03-09.
Lyell Immunopharma, Inc. (LYEL)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2026-03-06 | P, purchase reported on Form 4 | 488,090 | $12.5M | 2026-03-09 |
Vir Biotechnology, Inc. (VIR)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1723172) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms